Medication info
Olostajeng 10/5 milligrams (Olmesartan Medoxomil, Rosuvastatin)

Olostajeng 10/5 milligrams (Olmesartan Medoxomil, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletOlmesartan Medoxomil›10mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Daewoong Pharmaceutical
Appearance
Pale yellow round film-coated tablets
Packaging
30 tablets ((10 tablets/PTP) x 3), 30 tablets/bottle
Approval status
Active

MFDS item code 201506872 · Approved 2015.09.30 · Insurance code 641606160

Summary

Main use
Treatment of essential hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while monitoring their condition closely. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
Children under 18 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
(Co., Ltd.) Daewoong Pharmaceutical

Efficacy & effects

Treatment of essential hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to simultaneously take two ingredients, Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is effective in the treatment of essential hypertension. Rosuvastatin is primarily used as an adjunct therapy when hypercholesterolemia and hyperlipidemia are not controlled by diet and exercise. Additionally, it helps to slow the progression of atherosclerosis and reduce the risks of cardiovascular disease, stroke, myocardial infarction, and coronary revascularization. This medication manages both hypertension and hyperlipidemia, overall improving the cardiovascular health of patients.

How to take

Adult dose

This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while monitoring their condition closely. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

Children under 18 years: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, therefore it should be immediately discontinued upon confirmation of pregnancy. Women with hypersensitivity to this medication, pregnant or breastfeeding women, and fertile women not utilizing adequate contraceptive methods should not take this medication. Patients with very poor kidney function, those on dialysis, severe liver disease, bile duct obstruction, and those with certain liver diseases or muscle disorders should refrain from taking this medication. This medication contains lactose, and should not be administered to patients with lactose intolerance or related genetic issues. Patients with low blood pressure or decreased blood volume, those with impaired kidney function, and those at risk of hyperkalemia require special caution and regular monitoring of blood pressure, kidney function, and potassium levels when administering this medication. Dizziness may occur during the use of this medication, thus caution should be exercised when driving or operating dangerous machinery. Patients with a history of liver disease or those consuming alcohol excessively should undergo regular liver function tests before and during treatment with this medication. If symptoms of myalgia, muscle weakness, or cramps occur, they should be reported to a physician immediately, and muscle enzyme levels should be tested, with discontinuation if severe. This medication may interact with other drugs, so it's essential to inform the physician or pharmacist of any other medications being taken. Pregnant or planning to become pregnant women must consult a physician before taking this medication and should avoid it during pregnancy. Breastfeeding women should also consult a physician regarding the effects on the baby before deciding to take this medication. Safety and efficacy in pediatric patients under 18 years of age have not been established, so its use is not recommended. Elderly patients may have decreased bodily metabolism, thus dosage adjustments and caution are needed. In cases of overdose, symptoms such as hypotension and palpitations may occur, and immediate medical attention should be sought. This medication should be stored out of reach of children, and should not be transferred to other containers.

Side effects

Increase in ALT, increase in AST, elevated serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial swelling, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome resembling intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, orthostatic dizziness, increased blood pressure, low back pain, diarrhea, cough, epistaxis, upper respiratory infection, asthma, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, myopathy, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

30 tablets ((10 tablets/PTP) x 3), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.